

Vantictumab

Cat. No.:	HY-P9974
CAS No.:	1345009-45-1
Target:	Wnt
Pathway:	Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma ^{[1][2]} .
IC ₅₀ & Target	FZD1/2/5/7/8 ^{[1][2]} .

REFERENCES

[1]. Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. *Invest New Drugs*. 2020 Jun;38(3):821-830.

[2]. Diamond JR, et al. Phase 1b clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. *Breast Cancer Res Treat*. 2020 Nov;184(1):53-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA